Zantac Linked to Cancer
This Case involves:
Anyone who took either the prescription or over-the-counter strength of the heartburn-relief medication Zantac (ranitidine) and was later diagnosed with bladder or stomach cancer.
Class Action Lawsuits:
On September 13, 2019, the Food and Drug Administration (FDA) of the United States issued findings that Zantac was contaminated with the carcinogenic and hepatotoxic chemical N-nitrosodimethylamine (NDMA). NDMA is a component in aviation and rocket fuel, and in industrial lubricants. It also is a derivative of industrial processes like gasoline refining and treatment of nitrogen-containing wastewater. It is also found in many everyday food, beverage, cosmetic, and toiletry items. Zantac has been recalled and pulled from store shelves across the country.
Numerous lawsuits have been filed in the time since the FDA’s announcement, and thousands more are expected. As it is still early in the process, attorneys can only speculate as to the dollar value of a class-action suit or mass-tort litigation. However, some estimates target it in many billions of dollars.
Zantac is a medication that blocks the production of acid in the stomach. It is available over-the-counter and as a prescription. By blocking excessive stomach acid, damage to the espophagus, stomach, and duodenum -- including inflammation and ulcers -- is prevented or healed. Ranitidine, the drug comprising Zantac, was approved by the FDA in 1984. In addition to cancers, conditions that have been attributed to the use of Zantac include nervous system disorders, hepatitis and liver failure, arrhythmia and tachycardia, and low blood platelet levels.
If you would like more information about Zantac Mass Tort Litigation, please call our office at
601-296-1082 to discuss your case.